FDA Approves DEXMEDETOMIDINE HYDROCHLORIDE — Baxter Healthcare Corporation

Baxter Healthcare Corporation received FDA approval for its intravenous generic dexmedetomidine, a move expected to drive immediate price competition against the branded reference product and enhance operational margins within the sedation market. This market entry is anticipated to increase supply availability for hospitals while pressuring legacy manufacturers to adjust their pricing strategies.